EUVIMEDEUVIMED entdecken
Crossref

Expert opinion on the use of zanubrutinib in first-line treatment for chronic lymphocytic leukemia

Bartosz Puła, Krzysztof Jamroziak, Krzysztof Giannopoulos, Tomasz Wróbel, Lidia Gil, Robert Plisko, Iwona Hus, Tadeusz Robak

Acta Haematologica Polonica · 04.11.2026

DOI: 10.5603/ahp.114616 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica Polonica, online erschienen am 04.11.2026. Verfasst von Bartosz Puła und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Puła, B., Jamroziak, K., Giannopoulos, K., Wróbel, T., Gil, L., Plisko, R., Hus, I., & Robak, T. (2026). Expert opinion on the use of zanubrutinib in first-line treatment for chronic lymphocytic leukemia. Acta Haematologica Polonica. https://doi.org/10.5603/ahp.114616

Vancouver

Puła B, Jamroziak K, Giannopoulos K, Wróbel T, Gil L, Plisko R, et al. Expert opinion on the use of zanubrutinib in first-line treatment for chronic lymphocytic leukemia. Acta Haematologica Polonica. 2026. doi:10.5603/ahp.114616

BibTeX
@article{Pua2026,
  author = {Puła, Bartosz and Jamroziak, Krzysztof and Giannopoulos, Krzysztof and Wróbel, Tomasz and Gil, Lidia and Plisko, Robert and Hus, Iwona and Robak, Tadeusz},
  title = {Expert opinion on the use of zanubrutinib in first-line treatment for chronic lymphocytic leukemia},
  journal = {Acta Haematologica Polonica},
  year = {2026},
  doi = {10.5603/ahp.114616}
}
Kostenlos starten →